Last reviewed · How we verify
ranibizumab and dexamethasone — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
ranibizumab and dexamethasone (ranibizumab and dexamethasone) — Subhransu K. Ray, M.D., Ph.D..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| ranibizumab and dexamethasone TARGET | ranibizumab and dexamethasone | Subhransu K. Ray, M.D., Ph.D. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- ranibizumab and dexamethasone CI watch — RSS
- ranibizumab and dexamethasone CI watch — Atom
- ranibizumab and dexamethasone CI watch — JSON
- ranibizumab and dexamethasone alone — RSS
Cite this brief
Drug Landscape (2026). ranibizumab and dexamethasone — Competitive Intelligence Brief. https://druglandscape.com/ci/ranibizumab-and-dexamethasone. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab